Results 251 to 260 of about 218,137 (296)

Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing

Advanced Science, EarlyView.
Recent advances in smart nanotechnologies are expanding the toolbox for brain interfacing, from wireless neuromodulation and high‐resolution sensing to targeted delivery within the central nervous system. By combining responsive nanomaterials with bioinspired design, these platforms enable multimodal interactions with neurons and glia, while also ...
Tommaso Curiale, Marie Celine Lefevre, Alessio Carmignani, Maria Cristina Ceccarelli, Matteo Battaglini, Attilio Marino, Gianni Ciofani   +6 more
wiley   +1 more source

Role of Computed Tomography in Predicting Programmed Death Ligand-1 Positivity in Gastric Adenocarcinoma. [PDF]

J Multidiscip Healthc
Yu ZH, Ma WQ, Ren JW, Zhang XT, Chu L.
europepmc   +1 more source

Dextran sulfate inhibits the invasion, migration, and programmed death-ligand 1 expression in human gastric cancer cells by affecting the M2 tumor-associated macrophage polarization. [PDF]

Front Oncol
Shang J, Xu Y, Tao Y, Li B, Li M, Guo J, Yan L, Huang Y, Ma Q.   +8 more
europepmc   +1 more source

Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic review. [PDF]

Transl Lung Cancer Res
Soo RA, Lim DW, Yang JC, Shih JY, Herbst RS.   +4 more
europepmc   +1 more source

Relationship between <i>Helicobacter pylori</i> infection and programmed death-ligand 1 in gastric cancer: A meta-analysis. [PDF]

World J Clin Oncol
Yang HC, Fu CF, Qiao LJ, Long GH, Yang LF, Yao B.   +5 more
europepmc   +1 more source

Therapeutic Applications of Programmed Death Ligand 1 Inhibitors in Small Cell Lung Cancer. [PDF]

Biomedicines
Nabipur L, Mouawad M, Venketaraman V.
europepmc   +1 more source

Pescadillo ribosomal biogenesis factor 1 and programmed death-ligand 1 in gastric and head and neck squamous cell carcinoma. [PDF]

World J Gastroenterol
Hu XN, Li CF, Huang SM, Nie CL, Pang R.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma

Current Opinion in Oncology, 2015
The development of 'immune checkpoint inhibitors' or drugs targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has been a stunning success of cancer immunotherapy. This review provides a timely overview of the biology and function of the PD-1 pathway and discusses the rationale for therapeutic inhibition of this pathway in ...
Chan Yoon, Cheah, Nathan H, Fowler, Sattva S, Neelapu   +2 more
openaire   +3 more sources

Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations

JCO Precision Oncology, 2023
PURPOSE Programmed cell death protein-1 (PD-1) receptor and ligand interactions are the target of immunotherapies for more than 20 cancer types. Biomarkers that predict response to immunotherapy are microsatellite instability, tumor mutational burden, and programmed death ligand-1 (PD-L1) immunohistochemistry.
Emily L. Hoskins, Eric Samorodnitsky, Michele R. Wing, Julie W. Reeser, Julia F. Hopkins, Karthikeyan Murugesan, Zheng Kuang, Raven Vella, Leah Stein, Zachary Risch, Lianbo Yu, Serifat Adebola, Anoosha Paruchuri, John Carpten, Jad Chahoud, Stephen Edge, Jill Kolesar, Martin McCarter, Kenneth G. Nepple, Matthew Reilley, Courtney Scaife, Abhishek Tripathi, Nancy Single, Richard S.P. Huang, Lee A. Albacker, Sameek Roychowdhury   +25 more
openaire   +2 more sources